about
Genomic diversity of colorectal cancer: Changing landscape and emerging targetsAdjuvant therapy for pancreas cancer in an era of value based cancer careAmpullary cancer: an overviewUDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liverIdentifying and targeting cancer stem cells in the treatment of gastric cancer.Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer.A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.A phase I study of topotecan and gemcitabine in advanced solid tumors.Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trialsTherapeutic options for intrahepatic cholangiocarcinomaComprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2.The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experienceCurcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cellsPatients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series.A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel.Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignanciesBaseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabProstate cancer incidence in males with Lynch syndromeIncidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centersMulti-institutional phase II study of selumetinib in patients with metastatic biliary cancers.Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivoA phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapyA Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer.Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of diseaseCpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer.Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).
P50
Q26739052-18D0B4A3-F5A3-44F2-AD14-8532502DE32DQ26775916-04BF71C1-BBF4-44ED-A619-EE10E2BB5F3BQ27023881-7A204B6E-0AD8-459B-958A-06CB4F7A0715Q28252818-B9BACDCD-7DE2-4EE3-BFE3-AC200AC59E14Q30238811-359380B1-F440-4C50-82A2-5AE1E67B2D32Q33264095-472D9D26-5BF2-4A00-9B81-7A1566391603Q33265633-B049EC5D-EBD7-4720-95F9-BF97E278A4EBQ33384907-8E988B65-27C3-4B3F-9943-5BBBA62EEDEAQ33387995-D57D1338-E314-4569-912D-0DB58A725E9EQ33390366-AE1E6E94-DC4F-4253-AE42-01BFACE1F22CQ33401123-2C61D190-F6C7-4074-A6D7-39034ADD2D7AQ33402598-059848CF-2C0E-4B30-9C21-B2F1F78E97F1Q33408075-40624D5A-C355-456A-A10B-BE031EFFAB51Q33411308-C6EE337C-BAEC-4B14-AA1D-11C59808723DQ33418472-F08BF393-EE65-4A3E-9A4E-358B66CBB8DBQ33429801-2C12357F-7728-411A-B71C-A5BE64AC6A27Q33556487-D7C3F8D1-1A07-47F3-BA4B-F05530E117CEQ33621529-7569EB6D-9806-4542-925A-203D613B5127Q33640008-1BBB8EB8-5BD7-445C-A6F0-F27FC37A2F14Q33699802-36CA996F-101E-4AEE-B209-A53BEEBCB6FCQ33792279-EAD041B1-23C0-485C-952B-89953CB8F6DBQ33848817-F3447754-7820-4BC9-B813-37D4737C866AQ34260205-D5328CC8-7E7D-465E-A7E9-BFEEF2B238C6Q34419488-7A193AC9-B01E-47FF-BBCF-03661BC8973BQ34611637-1CA25C7C-01F5-449D-855D-8BFE268F0499Q34657411-2379BA34-6380-413A-8D06-F7A7A12ADC87Q34665177-C5ABA89F-AEFE-4A0C-A83D-F94E4262F5E2Q34665196-A6A2D714-F872-483B-950B-28F35E97AFFFQ34694813-17706581-A2AD-4671-88CC-F7ED96490F16Q34901622-0D79BAD7-319F-48BD-A638-AAB837FA873CQ34974875-2EC1522C-D586-4CC6-AC4D-7E50805D8B1DQ35023456-1F3EE1F2-FC5B-4F8D-939D-40B9C0C9A43CQ35073267-C679C924-48B0-4AA5-AFC0-9AA8ECFE7BD6Q35419253-5DF3E604-A5E6-4586-B474-021C0BC5E050Q35583855-37455848-8FB0-4209-BBF3-550228B7CB19Q35727558-B3633CBF-82C7-4C22-831B-CD323FA589D1Q35763725-AAF8624F-F61D-4912-8CE2-7961D56791A1Q35857561-DF5D5DF6-F000-47D4-B7B5-D9ED7AFDB077Q36075933-985A1C9C-5CCC-4EA6-8C61-8A713D4C3981Q36101895-7616935C-F194-4A93-AD60-F99997B19631
P50
description
onderzoeker
@nl
name
Tanios Bekaii-Saab
@ast
Tanios Bekaii-Saab
@en
Tanios Bekaii-Saab
@es
Tanios Bekaii-Saab
@nl
Tanios Bekaii-Saab
@sl
type
label
Tanios Bekaii-Saab
@ast
Tanios Bekaii-Saab
@en
Tanios Bekaii-Saab
@es
Tanios Bekaii-Saab
@nl
Tanios Bekaii-Saab
@sl
prefLabel
Tanios Bekaii-Saab
@ast
Tanios Bekaii-Saab
@en
Tanios Bekaii-Saab
@es
Tanios Bekaii-Saab
@nl
Tanios Bekaii-Saab
@sl